News

Visit GD3 at booth 1517 at the SOT 63rd Annual Meeting and ToxExpo Mar 10-14 in Salt Lake City, UT #1517

Press Releases

  • March 4, 2021

    Genesis Drug Discovery and Development acquires Integrated Analytical Solutions to add “off the shelf” PK profiling capabilities to its portfolio

    View
  • January 6, 2021

    Genesis Drug Discovery and Development expands its presence in the clinical space by acquiring STATKING Clinical Services

    View
  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Laura Sailor Veteran CRO Business Development Leader as Director of Business Development

    View
  • September 16, 2020

    Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer

    View
  • August 4, 2020

    Genesis Drug Discovery & Development (GD3) Announces Appointment of Anthony Rohr, as Chief Executive Officer of PharmOptima

    View
  • November 19, 2019

    Genesis Biotechnology Group acquires NEDP to grow the Preclinical Chemistry services portfolio of Genesis Drug Discovery & Development (GD3)

    View
  • June 18, 2019

    Genesis Drug Discovery & Development Expands Preclinical Contract Research Portfolio by Acquiring NexusPharma

    View
  • February 27, 2019

    Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.

    View
  • July 19, 2018

    Genesis Drug Discovery & Development Appoints Olesia Buiakova, M.D., Ph.D., as Chief Scientific Officer

    View
  • March 1, 2017

    Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima

    View